Last updated on July 2019

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo


Brief description of study

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a drug that looks like the study drug but contains no medication.) The usual chemotherapy in this study is paclitaxel (WP) and carboplatin followed by doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple negative breast cancer, no additional treatment is given unless the cancer returns. This study will also look at continuing treatment after surgery with atezolizumab or the placebo. To be better, atezolizumab given with the neoadjuvant therapy should be better at: 1) decreasing the amount of tumor in the breast than the placebo given with the usual chemotherapy and 2) decreasing the chance of the cancer from returning after surgery.

Another purpose of this study is to test the good and bad effects of atezolizumab when added to the usual chemotherapy. Atezolizumab may keep your cancer from growing but it can also cause side effects.

Detailed Study Description

NSABP B-59/GBG 96-GeparDouze is a prospective, randomized, double-blind, Phase III clinical trial. This is a collaborative study being conducted by NSABP Foundation, Inc. in partnership with the German Breast Group (GBG), and supported by funding by Genentech, a Member of the Roche Group, and F. Hoffmann-La Roche, Ltd.

In this clinical trial of neoadjuvant and adjuvant administration of atezolizumab/placebo in patients with high risk triple-negative breast cancer, the potential incremental efficacy and safety of neoadjuvant administration of atezolizumab/placebo with a sequential regimen of weekly paclitaxel with every-3-week carboplatin followed immediately by neoadjuvant administration of atezolizumab/placebo with AC/EC will be evaluated. Patients will then undergo surgery. Following recovery from surgery, patients will initiate approximately 6 months of adjuvant therapy with atezolizumab/placebo and receive the same investigational agent they received pre-operatively. Administration of radiation therapy will be based on local standards at the discretion of patients and investigators, but if administered, atezolizumab/placebo will be administered concurrently.

The primary aims of the study are 1) to determine value of atezolizumab in improving pathologic complete response in the breast and post-therapy lymph nodes evaluated histologically (pCR breast and nodes [(ypT0/Tis ypN0)]), and 2) to determine the value of atezolizumab in improving event-free survival (EFS). Secondary aims include: pathologic complete response in the breast (ypT0/Tis); pathologic complete response in the breast and lymph nodes (ypT0 ypN0); positive nodal status conversion rate; overall survival; recurrence-free interval: distant disease-free survival; brain metastases free survival; and toxicity. The stratification factors for the study are: 1) clinical size of the primary tumor (1.1-3.0 cm; > 3.0 cm); 2) nodal status as determined by protocol-specified criteria (negative, positive); 3) AC/EC (every 2 weeks; every 3 weeks); and 4) Region (North America; Europe).

For patient eligibility, local testing on the diagnostic core must have determined the patient's tumor to be ER-negative, PgR-negative, and HER2-negative by current ASCO/CAP guidelines. Material from either the diagnostic core biopsy or the research biopsy must be sent for central testing for confirmation of ER, PgR, and HER2 to confirm eligibility. If local testing has determined a tumor to be HER2 equivocal or to have a borderline ER/PgR status (% IHC staining < 10% for both), material may be submitted for central testing to determine eligibility.

In order to proactively identify and further assess any cardiac toxicity that may occur with the combination of anthracyclines and atezolizumab, this study includes a cardiac safety lead-in for the first 60 patients who initiate AC/EC. The safety lead-in will consist of assessment of ECG and serum troponin-T obtained just prior to administration of the first dose of AC/EC, following completion of the administration of the 1st and 3rd cycle of AC/EC prior to initiation of the atezolizumab/placebo. An additional assessment of LVEF with echocardiogram or MUGA scan will also be obtained prior to the 3rd dose of AC/EC. In order to provide an early assessment of cardiac safety, results of the troponin-T assessments, ECGs, LVEF assessment, and cardiac safety data will be evaluated by the Data Safety Monitoring Board (DSMB) when the last of the initial 20 patients who initiate AC/EC undergo their scheduled post-surgery LVEF assessment. When the last of the first 60 patients to initiate AC/EC undergo their scheduled post-surgery LVEF assessment, results of the troponin assessments, ECGs, LVEF assessments, and cardiac safety data from all 60 patients will be evaluated by the DSMB.

Research core biopsies of breast primary at baseline and 1-4 days prior to the second dose of atezolizumab/placebo are a study requirement for all patients. One to three representative blocks of residual primary tumor containing the maximum amount of tumor and node with the largest focus of metastasis is required from the definitive breast surgery if gross residual disease is greater than or equal to 1.0 cm. If gross residual disease is less than 1.0 cm, tissue should be submitted, if possible. Blood specimens will be collected on all patients at baseline for exploratory biomarker analysis and to support future correlative studies.

Accrual for this study will be 1,520 randomized patients. It is expected that approximately 760 patients will be randomized by sites in North America and approximately 760 patients, by sites in Europe.

Clinical Study Identifier: NCT03281954

Find a site near you

Start Over

Katmai Oncology Group

Anchorage, AK United States
  Connect »

Kaiser Permanente-Anaheim

Anaheim, CA United States
  Connect »

Kaiser Permanente-Baldwin Park

Baldwin Park, CA United States
  Connect »

Kaiser Permanente-Bellflower

Bellflower, CA United States
  Connect »

Kaiser Permanente-Fontana

Fontana, CA United States
  Connect »

Kaiser Permanente-Harbor City

Harbor City, CA United States
  Connect »

Kaiser Permanente-Irvine

Irvine, CA United States
  Connect »

Kaiser Permanente-Sunset

Los Angeles, CA United States
  Connect »

Kaiser Permanente-Panorama City

Panorama City, CA United States
  Connect »

Kaiser Permanente-Riverside

Riverside, CA United States
  Connect »

Kaiser Permanente-Zion

San Diego, CA United States
  Connect »

Kaiser Permanente- San Marcos

San Marcos, CA United States
  Connect »

Kaiser Permanente-Woodland Hills

Woodland Hills, CA United States
  Connect »

Illinois Cancer Care-Bloomington

Bloomington, IL United States
  Connect »

Decatur Memorial Hospital

Decatur, IL United States
  Connect »

Crossroads Cancer Center

Effingham, IL United States
  Connect »

Illinois Cancer Care-Galesburg

Galesburg, IL United States
  Connect »

Edward Cancer Center

Naperville, IL United States
  Connect »

Illinois Cancer Care PC

Peoria, IL United States
  Connect »

Edward Cancer Center Plainfield

Plainfield, IL United States
  Connect »

Ochsner Medical Center

New Orleans, LA United States
  Connect »

Maryland Oncology Hematology

Bethesda, MD United States
  Connect »

Maryland Oncology Hematology

Rockville, MD United States
  Connect »

Holy Cross Hospital

Silver Spring, MD United States
  Connect »

Michigan State University

East Lansing, MI United States
  Connect »

Health Quest Medical Practice

Poughkeepsie, NY United States
  Connect »

Vassar Brothers Medical Center

Poughkeepsie, NY United States
  Connect »

RHOA of Cary

Cary, NC United States
  Connect »

RHOA of Garner

Garner, NC United States
  Connect »

Rex Cancer Center

Raleigh, NC United States
  Connect »

RHOA of Blue Ridge

Raleigh, NC United States
  Connect »

RCC of Wakefield

Raleigh, NC United States
  Connect »

Aultman Hospital

Canton, OH United States
  Connect »

Ephrata Cancer Center

Ephrata, PA United States
  Connect »

St. Vincent Hospital

Erie, PA United States
  Connect »

Wellspan Medical Oncology

Gettysburg, PA United States
  Connect »

AHN Cancer Institute at Jefferson

Jefferson Hills, PA United States
  Connect »

Forbes Regional Hospital

Monroeville, PA United States
  Connect »

Allegheny General Hospital

Pittsburgh, PA United States
  Connect »

WPAON at AGH

Pittsburgh, PA United States
  Connect »

WPAON at WPH

Pittsburgh, PA United States
  Connect »

Western Pennsylvania Hospital

Pittsburgh, PA United States
  Connect »

Women's and Infants Hospital

Providence, RI United States
  Connect »

Spartanburg Medical Center

Spartanburg, SC United States
  Connect »

Wellmont Cancer Institute

Johnson City, TN United States
  Connect »

Wellmont Cancer Institute

Kingsport, TN United States
  Connect »

MRCC Auburn

Auburn, WA United States
  Connect »

MRCC Gig Harbor

Gig Harbor, WA United States
  Connect »

MRCC Puyallup

Puyallup, WA United States
  Connect »

MultiCare Health System

Tacoma, WA United States
  Connect »

West Virginia University

Morgantown, WV United States
  Connect »

Aurora Health Center Fond du Lac

Fond Du Lac, WI United States
  Connect »

Aurora Cancer Care-Grafton

Grafton, WI United States
  Connect »

Aurora BayCare Medical Center

Green Bay, WI United States
  Connect »

Aurora Cancer Care

Milwaukee, WI United States
  Connect »

Aurora Sinai Medical Center

Milwaukee, WI United States
  Connect »

Aurora Cancer Care-Racine

Racine, WI United States
  Connect »

Aurora Cancer Care

Wauwatosa, WI United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.